Skip to main content
SpringerLink
Log in

Valori di soglia: una scomoda necessità

  • Editoriale
  • Published:
PharmacoEconomics Italian Research Articles

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. http://www.pcori.org

  2. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253–8

    Article  PubMed  CAS  Google Scholar 

  3. Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med 2010; 363: 1495–7

    Article  PubMed  Google Scholar 

  4. Neumann PJ, Greenberg D. Is the United States ready for QALYs? Health Affairs 2009; 28: 1366–71

    Article  PubMed  Google Scholar 

  5. Bridges JFP, Onukwugha E, Mullins CD. Healthcare rationing by proxy. Cost-effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics 2010; 28: 175–84

    Article  PubMed  Google Scholar 

  6. Mooney G, Blackwell S. Whose health service is it anyway? Med J Aust 2004; 180: 76–8

    PubMed  Google Scholar 

  7. Culyer A, McCabe C, Briggs A, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy 2007; 12: 56–8

    Article  PubMed  Google Scholar 

  8. http://www.ec.europa.eu/research/fp6/ssp/eurovaq_en.htm

  9. Gyrd-Hansen D. Looking for willingness to pay (WTP) threshold for a QALY — Does it make sense? A Critical View. ISPOR Connections 2007; 13: 5–8

    Google Scholar 

  10. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: What it is and what that means. Pharmacoeconomics 2008; 26: 733–44

    Article  PubMed  Google Scholar 

  11. Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practice — Budget impact analysis. Value Health 2007; 10: 336–47

    Article  PubMed  Google Scholar 

  12. McKenna C, Chalabi Z, Epstein D, et al. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. J Health Econ 2010; 29: 170–81

    Article  PubMed  Google Scholar 

  13. Buxton M. Looking for willingness to pay (WTP) threshold for a QALY — Does it make sense? A Practical View. ISPOR Connections 2007; 13: 9–11

    Google Scholar 

  14. Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in health care decisions. Int J Technol Assess Health Care 2011; 27: 71–6

    Article  PubMed  Google Scholar 

  15. Sculpher M. Single Technology Appraisal at the UK National Institute for Health and Clinical Excellence. A source of evidence and analysis for decision making internationally. Pharmacoeconomics 2010; 28: 347–9

    Article  PubMed  Google Scholar 

  16. Rodgers M, Griffin S, Paulden M, et al. Altretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics 2010; 28: 351–62

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health, Milano, Italia

    Carlo Lucioni (Editor in chief)

Authors
  1. Carlo Lucioni
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lucioni, C. Valori di soglia: una scomoda necessità. Pharmacoeconomics-Ital-Res-Articles 13, 1–4 (2011). https://doi.org/10.1007/BF03320678

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03320678

Search

Navigation